BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
-$0.03 today
- Market cap
- $144.85M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
Volume 0.58M
Average 0.37M
BBOT Common Stock
The par or stated value of issued common shares, plus paid-in capital where reported together.
BridgeBio Oncology Therapeutics Inc.NASDAQ: BBOT
Common Stock · Q1 FY2026 · quarter ended Mar 2026
Common stock remains negative
Q1 FY2026 common stock was $8K, compared with $0 a year earlier. Over 3 fiscal years it compounded at +202.9% a year.
Context
- Common stock amounted to 0.0% of total assets at the end of Q1 FY2026, unchanged from a year earlier.
- Common stock increased in 2 of the last 3 fiscal years.
Sources:Balance SheetText generated from reported figures; not investment advice.
Common Stock history
USD · from the balance sheet
- Latest · FY2025
- 8K USD
- Year-over-year change
- -100.0%
- 4-year CAGR
- +129.6%
| Period | Period end | Common Stock | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 8K | -100.0% |
| FY2024 | 2024-12-31 | 192.45M | +41836813.5% |
| FY2023 | 2023-12-31 | 460 | +59.7% |
| FY2022 | 2022-12-31 | 288 | +0.0% |
| FY2021 | 2021-12-31 | 288 | — |
Common Stock vs competitors
How BBOT compares with its peers on the latest reported figures
- Peers report in different currencies, so common stock is compared through growth and share of total assets rather than absolute size.
- Common stock amounts to 0.0% of total assets for BBOT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $744K USD | +4.2% | +6.1% | 0.1% | |
| Mar 2026 | CHF 618.15K CHF | +11.4% | +147.0% | 0.3% | |
| Sep 2026 | $169K USD | +50.9% | +15.6% | 0.0% | |
| Mar 2026 | $134K USD | +6.3% | +28.3% | 0.1% | |
| Aug 2026 | $109K USD | +41.6% | +29.5% | 0.0% | |
SEPNSepterna, Inc. | Sep 2026 | $47K USD | +4.4% | +146.6% | 0.0% |
| Mar 2026 | $29K USD | -3.3% | -1.2% | 0.0% | |
BBOTBridgeBio Oncology Therapeutics Inc. | Mar 2026 | $8K USD | — | +202.9% | 0.0% |
| Mar 2026 | $7K USD | +16.7% | +26.0% | 0.0% | |
| Sep 2026 | $6K USD | +20.0% | +6.3% | 0.0% | |
| Peer median (excluding BBOT) | — | +11.4% | +26.0% | 0.0% | |
Competitors are the stored peer set for BBOT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
Intrinsic Alpha fair value
Locked
Current Price
$1.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.